Literature DB >> 9234763

Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice.

E T Ryan1, J R Butterton, T Zhang, M A Baker, S L Stanley, S B Calderwood.   

Abstract

Entamoeba histolytica is a significant cause of morbidity and mortality worldwide. The serine-rich E. histolytica protein (SREHP) is a surface-expressed trophozoite protein that includes multiple hydrophilic tandem repeats. A purified fusion protein between the dodecapeptide repeat of SREHP and cholera toxin B subunit (CTB) has previously been shown to be immunogenic in mice after oral inoculation when cholera toxin is coadministered as an immunoadjuvant. We engineered a live attenuated El Tor Vibrio cholerae vaccine strain, Peru2, to express the SREHP-12-CTB fusion protein to the supernatant from either a plasmid [Peru2 (pETR5.1)] or from a chromosomal insertion (ETR3). Vector strains were administered orally to germfree mice that were subsequently housed under nongermfree conditions; mice received one (day 0) or two (days 0 and 14) inoculations. No immunoadjuvant or cholera holotoxin was administered. Mice that received two inoculations of Peru2(pETR5.1) had the most pronounced antiamebic systemic and mucosal immunologic responses. Less marked, but significant, anti-SREHP serum immunoglobulin G antibody responses were also induced in mice that received either one or two oral inoculations of strain ETR3. Anti-V. cholerae responses were also induced, as measured by the induction of serum vibriocidal antibodies and by serum and mucosal anti-CTB antibody responses. These results suggest that V. cholerae vector strains can be successful delivery vehicles for the SREHP-12-CTB fusion protein, to induce mucosal and systemic antiamebic and anti-V. cholerae immune responses. The magnitude of these responses is proportional to the amount of SREHP-12-CTB produced by the vector strain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234763      PMCID: PMC175440          DOI: 10.1128/iai.65.8.3118-3125.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

1.  THE TOXIC EFFECT OF ENTAMOEBA HISTOLYTICA ON LEUCOCYTES.

Authors:  R JARUMILINTA; F KRADOLFER
Journal:  Ann Trop Med Parasitol       Date:  1964-09

Review 2.  Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.

Authors:  J Holmgren; C Czerkinsky; N Lycke; A M Svennerholm
Journal:  Am J Trop Med Hyg       Date:  1994       Impact factor: 2.345

3.  An optimized freeze-squeeze method for the recovery of DNA fragments from agarose gels.

Authors:  D Tautz; M Renz
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

4.  Genetic fusion of a non-toxic heat-stable enterotoxin-related decapeptide antigen to cholera toxin B-subunit.

Authors:  J Sanchez; A M Svennerholm; J Holmgren
Journal:  FEBS Lett       Date:  1988-12-05       Impact factor: 4.124

5.  Cloning and expression of a membrane antigen of Entamoeba histolytica possessing multiple tandem repeats.

Authors:  S L Stanley; A Becker; C Kunz-Jenkins; L Foster; E Li
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

6.  Use of the Vibrio cholerae irgA gene as a locus for insertion and expression of heterologous antigens in cholera vaccine strains.

Authors:  J R Butterton; S A Boyko; S B Calderwood
Journal:  Vaccine       Date:  1993-10       Impact factor: 3.641

Review 7.  Emergence of a new cholera pandemic: molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype.

Authors:  M K Waldor; J J Mekalanos
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

8.  Duration of infection-derived immunity to cholera.

Authors:  M M Levine; R E Black; M L Clements; L Cisneros; D R Nalin; C R Young
Journal:  J Infect Dis       Date:  1981-06       Impact factor: 5.226

9.  Development of a live, oral, attenuated vaccine against El Tor cholera.

Authors:  D N Taylor; K P Killeen; D C Hack; J R Kenner; T S Coster; D T Beattie; J Ezzell; T Hyman; A Trofa; M H Sjogren
Journal:  J Infect Dis       Date:  1994-12       Impact factor: 5.226

10.  Oral immunization with the dodecapeptide repeat of the serine-rich Entamoeba histolytica protein (SREHP) fused to the cholera toxin B subunit induces a mucosal and systemic anti-SREHP antibody response.

Authors:  T Zhang; E Li; S L Stanley
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

View more
  26 in total

1.  A cloning vector for efficient generation of cholera toxin B gene fusions for epitope screening.

Authors:  I Secundino; J Paniagua-Solís; A Isibasi; J Sanchez
Journal:  Mol Biotechnol       Date:  1999-02       Impact factor: 2.695

Review 2.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

3.  Optimizing the germfree mouse model for in vivo evaluation of oral Vibrio cholerae vaccine and vector strains.

Authors:  T I Crean; M John; S B Calderwood; E T Ryan
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

4.  Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice.

Authors:  Julianne E Rollenhagen; Anuj Kalsy; Rina Saksena; Alaullah Sheikh; Mohammad Murshid Alam; Firdausi Qadri; Stephen B Calderwood; Pavol Kovác; Edward T Ryan
Journal:  Vaccine       Date:  2009-06-27       Impact factor: 3.641

Review 5.  Progress towards development of a vaccine for amebiasis.

Authors:  S L Stanley
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

6.  Comparative proteomic analysis reveals activation of mucosal innate immune signaling pathways during cholera.

Authors:  Crystal N Ellis; Regina C LaRocque; Taher Uddin; Bryan Krastins; Leslie M Mayo-Smith; David Sarracino; Elinor K Karlsson; Atiqur Rahman; Tahmina Shirin; Taufiqur R Bhuiyan; Fahima Chowdhury; Ashraful Islam Khan; Edward T Ryan; Stephen B Calderwood; Firdausi Qadri; Jason B Harris
Journal:  Infect Immun       Date:  2015-01-05       Impact factor: 3.441

Review 7.  The future for vaccine development against Entamoeba histolytica.

Authors:  Jeanie Quach; Joëlle St-Pierre; Kris Chadee
Journal:  Hum Vaccin Immunother       Date:  2014-02-06       Impact factor: 3.452

8.  The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A immune responses in patients with cholera caused by Vibrio cholerae O1 and O139.

Authors:  Muhammad Asaduzzaman; Edward T Ryan; Manohar John; Long Hang; Ashraful I Khan; A S G Faruque; Ronald K Taylor; Stephen B Calderwood; Firdausi Qadri
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

9.  Construction of a Vibrio cholerae prototype vaccine strain O395-N1-E1 which accumulates cell-associated cholera toxin B subunit.

Authors:  Gi-eun Rhie; Hae-Mi Jung; Bong Su Kim; John J Mekalanos
Journal:  Vaccine       Date:  2008-06-26       Impact factor: 3.641

10.  Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108.

Authors:  Weili Liang; Shixia Wang; Fenggang Yu; Lijuan Zhang; Guoming Qi; Yanqing Liu; Shouyi Gao; Biao Kan
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.